Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20636107 | 0.94 | GSTO1 (0.35) | GSTO1NLRP3 | |
| SCHEMBL20635000 | 0.92 | NLRP3 (0.40) | DPP4DPP8DPP7GSTO1NLRP3 | |
| SCHEMBL22433582 | 0.90 | MEN1 (0.43) | — | |
| SCHEMBL20634988 | 0.89 | GSTO1 (0.36) | GSTO1NLRP3 | |
| SCHEMBL20636097 | 0.86 | NLRP3 (0.41) | GSTO1NLRP3 | |
| SCHEMBL20635004 | 0.84 | GSTO1 (0.37) | GSTO1NLRP3 | |
| SCHEMBL20636092 | 0.84 | MEN1 (0.44) | — | |
| SCHEMBL24922558 | 0.83 | GSTO1 (0.36) | GSTO1NLRP3 | |
| SCHEMBL22433584 | 0.83 | GSTO1 (0.36) | GSTO1NLRP3 | |
| SCHEMBL22433597 | 0.81 | GSTO1 (0.34) | GSTO1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | PER2 2333/4885DPP4 80/4885DPP8 239/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | PER2 2369/4885DPP4 74/4885DPP8 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.